MS-based monitoring of proteolytic decay of synthetic reporter peptides for quality control of plasma and serum specimens

American Journal of Clinical Pathology

Volumn 140, Issue 3, 2013, Pages 314-323

  Findeisen, Peter ^a   Thumfart, Jörg Oliver ^a   Costina, Victor ^a   Hofheinz, Ralf ^a   Neumaier, Michael ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Biobanking; Decay; Mass spectrometry; Plasma; Protease; Quality assessment; Reporter peptides; Serum

Indexed keywords

AMINO ACID SEQUENCE; ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; INCUBATION TIME; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; PLASMA; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEOMICS; QUALITY CONTROL; RECEIVER OPERATING CHARACTERISTIC; REPRODUCIBILITY; SERUM; TANDEM MASS SPECTROMETRY;

BIOBANKING; DECAY; MASS SPECTROMETRY; PLASMA; PROTEASE; QUALITY ASSESSMENT; REPORTER PEPTIDES; SERUM;

BLOOD SPECIMEN COLLECTION; HUMANS; MASS SPECTROMETRY; PEPTIDES; PROTEOLYSIS; PROTEOMICS; QUALITY CONTROL;

EID: 84882773610     PISSN: 00029173     EISSN: 19437722     Source Type: Journal    
DOI: 10.1309/AJCPOS9Z5KVZSFSC     Document Type: Article

References (33)

1. Yi J, Liu Z, Craft D, et al. Intrinsic peptidase activity causes a sequential multi-step reaction (SMSR) in digestion of human plasma peptides. J Proteome Res. 2008;7:5112-5118.
2. Findeisen P, Sismanidis D, Riedl M, et al. Preanalytical impact of sample handling on proteome profiling experiments with matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Clin Chem. 2005;51:2409-2411.
3. Guder W. Use of Anticoagulants in Diagnostic Laboratory Investigations and Stability of Blood, Plasma and Serum Samples. Geneva, Switzerland: World Health Organization; 2002. WHO/DIL/LAB/991 Rev2.
4. Karsan A, Eigl B, Flibotte S, et al. Analytical and preanalytical biases in serum proteomic pattern analysis for breast cancer diagnosis. Clin Chem. 2005;51:1525-1528.
5. McLerran D, Grizzle WE, Feng Z, et al. Analytical validation of serum proteomic profiling for diagnosis of prostate cancer: sources of sample bias. Clin Chem. 2008;54:44-52.
6. McLerran D, Grizzle WE, Feng Z, et al. SELDI-TOF MS whole serum proteomic profiling with IMAC surface does not reliably detect prostate cancer. Clin Chem. 2008;54:53-60.
7. Govorukhina NI, de Vries M, Reijmers TH, et al. Influence of clotting time on the protein composition of serum samples based on LC-MS data. J Chromatogr. 2009;877:1281-1291.
8. Betsou F, Barnes R, Burke T, et al. Human biospecimen research: experimental protocol and quality control tools. Cancer Epidemiol Biomarkers Prev. 2009;18:1017-1025.
9. Niessen S, Hoover H, Gale AJ. Proteomic analysis of the coagulation reaction in plasma and whole blood using PROTOMAP. Proteomics. 2011;11:2377-2388.
10. Wildes D, Wells JA. Sampling the N-terminal proteome of human blood. Proc Natl Acad Sci U S A. 2010;107:4561-4566.
11. Powell MF, Grey H, Gaeta F, et al. Peptide stability in drug development: a comparison of peptide reactivity in different biological media. J Pharm Sci. 1992;81:731-735.
12. Peccerella T, Lukan N, Hofheinz R, et al. Endoprotease profiling with double-tagged peptide substrates: a new diagnostic approach in oncology. Clin Chem. 2010;56:272-280.
13. Findeisen P, Neumaier M. Functional protease profiling for diagnosis of malignant disease. Proteomics Clin Appl. 2012;6:60-78.
14. Rawlings ND, Morton FR, Kok CY, et al. MEROPS: the peptidase database. Nucleic Acids Res. 2008;36:D320-D325.
15. Villanueva J, Shaffer DR, Philip J, et al. Differential exoprotease activities confer tumor-specific serum peptidome patterns. J Clin Invest. 2006;116:271-284.
16. Rifai N, Gillette M, Carr S. Protein biomarker discovery and validation: the long and uncertain path to clinical utility. Nat Biotechnol. 2006;24:971-983.
17. Anderson NL. The clinical plasma proteome: a survey of clinical assays for proteins in plasma and serum. Clin Chem. 2010;56:177-185.
18. Findeisen P, Neumaier M. Mass spectrometry based proteomics profiling as diagnostic tool in oncology: current status and future perspective. Clin Chem Lab Med. 2009;47:666-684.
19. Ransohoff DF, Gourlay ML. Sources of bias in specimens for research about molecular markers for cancer. J Clin Oncol. 2010;28:698-704.
20. Umemura H, Nezu M, Kodera Y, et al. Effects of the time intervals between venipuncture and serum preparation for serum peptidome analysis by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Clin Chim Acta. 2009;406:179-180.
21. Mangerini R, Romano P, Facchiano A, et al. The application of atmospheric pressure matrix-assisted laser desorption/ionization to the analysis of long-term cryopreserved serum peptidome. Anal Biochem. 2011;417:174-181.
22. van den Broek I, Sparidans RW, Schellens JH, et al. Specific investigation of sample handling effects on protease activities and absolute serum concentrations of various putative peptidome cancer biomarkers. Clin Proteomics. 2010;6:115-127.
23. Doherty NS, Littman BH, Reilly K, et al. Analysis of changes in acute-phase plasma proteins in an acute inflammatory response and in rheumatoid arthritis using two-dimensional gel electrophoresis. Electrophoresis. 1998;19:355-363.
24. Nedelkov D, Phillips DA, Tubbs KA, et al. Investigation of human protein variants and their frequency in the general population. Mol Cell Proteomics. 2007;6:1183-1187.
25. Findeisen P, Post S, Wenz F, et al. Addition of exogenous reporter peptides to serum samples before mass spectrometrybased protease profiling provides advantages over profiling of endogenous peptides. Clin Chem. 2007;53:1864-1866.
26. Sanderink GJ, Artur Y, Siest G. Human aminopeptidases: a review of the literature. J Clin Chem Clin Biochem. 1988;26:795-807.
27. Hortin GL, Sviridov D, Anderson NL. High-abundance polypeptides of the human plasma proteome comprising the top 4 logs of polypeptide abundance. Clin Chem. 2008;54:1608-1616.
28. Murao N, Ishigai M, Yasuno H, et al. Simple and sensitive quantification of bioactive peptides in biological matrices using liquid chromatography/ selected reaction monitoring mass spectrometry coupled with trichloroacetic acid clean-up. Rapid Commun Mass Spectrom. 2007;21:4033-4038.
29. Lippi G, Guidi GC, Mattiuzzi C, et al. Preanalytical variability: the dark side of the moon in laboratory testing. Clin Chem Lab Med. 2006;44:358-365.
30. Banks RE. Preanalytical influences in clinical proteomic studies: raising awareness of fundamental issues in sample banking. Clin Chem. 2008;54:6-7.
31. Schrohl AS, Wurtz S, Kohn E, et al. Banking of biological fluids for studies of disease-associated protein biomarkers. Mol Cell Proteomics. 2008;7:2061-2066.
32. Rouy D, Ernens I, Jeanty C, et al. Plasma storage at -80 degrees C does not protect matrix metalloproteinase-9 from degradation. Anal Biochem. 2005;338:294-298.
33. Mitchell BL, Yasui Y, Li CI, et al. Impact of freeze-thaw cycles and storage time on plasma samples used in mass spectrometry based biomarker discovery projects. Cancer Inform. 2005;1:98-104.